“…hence, to enhance the anticancer activity of genistein at lower concentrations, we have synthesized seven structurally modified derivatives of genistein (Ma-6, Ma-8, Ma-11, Ma-19, Ma-20, Ma-21 and Ma-22) based on the structural requirements for an optimal anticancer effect. among those seven, three derivatives (Ma-6, Ma-8 and Ma- 19) showed high antiproliferative activity with IC 50 levels in the range of 1-2.5 μM, i.e., at much lower concentrations range than genistein itself, in three eR-positive breast cancer cell lines (MCF-7, 21pT and T47D) studied. In our analysis, we noticed that at IC 50 concentrations, the Ma-6, Ma-8 and Ma-19 genistein derivatives induced apoptosis, inhibited eRα messenger RNa expression and increased the ratio of eRβ to eRα levels in a manner comparable to the parent compound genistein.…”